Efficacy observation of surgical operation combined with neoadjuvant concurrent chemoradiotherapy before operation for middle and lower rectal carcinoma in phase Ⅱ and Ⅲ
10.3760/cma.j.issn.1006-9801.2018.02.007
- VernacularTitle:手术联合术前新辅助同步放化疗治疗Ⅱ～Ⅲ期中低位直肠癌效果观察
- Author:
Tao PENG
1
;
Zhan LOU
;
Yongjiang YANG
;
Yifeng ZHAO
;
Shuguang LI
Author Information
1. 河北北方学院附属第一医院消化内镜中心
- Keywords:
Rectal neoplasms;
Chemotherapy;
adjuvant;
Radiotherapy;
adjuvant;
Total mesorectal excision
- From:
Cancer Research and Clinic
2018;30(2):103-106
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the application value of surgical operation combined with neoadjuvant chemoradiation therapy for rectal carcinoma in phase Ⅱ and Ⅲ and to evaluate the effect of surgical resection. Methods A retrospective analysis was performed from January 2012 to January 2017, including 70 cases of middle and lower rectal carcinoma in phase ⅡandⅢin the First Affiliated Hospital of Hebei North University.Neoadjuvant concurrent chemoradiotherapy before operation was applied.Neoadjuvant radiotherapy: total dose 50 Gy, 2.0 Gy for once, 5 times per week, 5 weeks in total, the radiation field 5 wild for pelvic irradiation. Neoadjuvant chemotherapy: XELOX (oxaliplatin, capecitabine) / FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil) was used for synchronous chemotherapy. After radiotherapy, the patients received surgery in 6-8 weeks. All the operations were performed according to the total mesorectum excision (TME) specification.Results A total of 70 patients underwent neoadjuvant concurrent chemoradiotherapy.The adverse effect rate was 15.71 % (11/70) of gradeⅠand 7.14 % (5/70) of gradeⅡ. No gradeⅢandⅣadverse reactions occurred. The tumor stage of 94.29 % (66/70) patients reduced. The TNM stage of the postoperation was decreased compared with that before neoadjuvant chemoradiotherapy (χ 2= 7.846, P < 0.05). Tumor resection rate was 94.29 % (66/70). Conclusion Surgical operation combined with neoadjuvant concurrent chemoradiotherapy before operation for middle and lower rectal carcinoma in phase ⅡandⅢhas a favorable efficacy and safety,which can alleviate the tumor staging and increase the eradication rate of tumors.
